NNC0143-0406

NNC0143-0406 is an investigational basal insulin analog developed by Novo Nordisk for the treatment of type 1 diabetes mellitus. It was studied in phase 1 clinical trials to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics when administered as a single subcutaneous dose in subjects with type 1 diabetes. The mechanism of action is presumed to be similar to other insulins—acting as a replacement for endogenous insulin by binding to the insulin receptor and facilitating glucose uptake—but specific mechanistic details have not been published. The drug has not received regulatory approval and no brand names are associated with it[1][2][4][9][10].